Study: NCT03991936

Adverse event: Onychomadesis
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 3/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 0/17 in the TAC 5.0 mg/mL group 3/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 2 affected / 10 at risk

Adverse event: Nail bed bleeding
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 0/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Cuticle retraction
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 3/17 in the TAC 5.0 mg/mL group 6/16 in the TAC 7.5 mg/mL group 6/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Beau's line(s)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Erythronychia
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 2/16 in the TAC 7.5 mg/mL group 2/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Nail bed bleeding
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 0/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Cuticle retraction
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 3/17 in the TAC 5.0 mg/mL group 6/16 in the TAC 7.5 mg/mL group 6/14 in the TAC 10 mg/mL group
Frequency: 3 affected / 10 at risk

Adverse event: Beau's line(s)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Erythronychia
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 2/16 in the TAC 7.5 mg/mL group 2/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Onychomadesis
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 3/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 0/17 in the TAC 5.0 mg/mL group 3/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 2 affected / 10 at risk

Adverse event: Nail bed bleeding
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 0/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Cuticle retraction
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 3/17 in the TAC 5.0 mg/mL group 6/16 in the TAC 7.5 mg/mL group 6/14 in the TAC 10 mg/mL group
Frequency: 4 affected / 10 at risk

Adverse event: Longitudinal groove
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 0/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 0/17 in the TAC 5.0 mg/mL group 2/16 in the TAC 7.5 mg/mL group 0/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Beau's line(s)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Erythronychia
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 2/16 in the TAC 7.5 mg/mL group 2/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Onychomadesis
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 3/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 0/17 in the TAC 5.0 mg/mL group 3/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Cuticle retraction
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 3/17 in the TAC 5.0 mg/mL group 6/16 in the TAC 7.5 mg/mL group 6/14 in the TAC 10 mg/mL group
Frequency: 4 affected / 10 at risk

Adverse event: Beau's line(s)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 1/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Erythronychia
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 1/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 1/17 in the TAC 5.0 mg/mL group 2/16 in the TAC 7.5 mg/mL group 2/14 in the TAC 10 mg/mL group
Frequency: 2 affected / 10 at risk

Adverse event: Nail plate split
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 0/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 0/17 in the TAC 5.0 mg/mL group 0/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk

Adverse event: Nail plate concavity
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Units (fingernails) affected/at risk:

0/10 in the Placebo group 0/16 in the triamcinolone acetonide (TAC) 2.5 mg/mL group 0/17 in the TAC 5.0 mg/mL group 0/16 in the TAC 7.5 mg/mL group 1/14 in the TAC 10 mg/mL group
Frequency: 1 affected / 10 at risk